Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides…
- Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 – - Demonstrated evidence of target engagement for…